Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in <i>EGFR</i> -Mutant Lung Cancer

Abstract

Patients with EGFR-mutant lung cancer develop acquired resistance to EGFR and mutant-selective EGFR tyrosine kinase inhibitors. Here, we show that cotargeting EGFR and MEK can prevent the emergence of a broad variety of drug resistance mechanisms in vitro and in vivo and may be a superior therapeutic regimen for these patients.